Drug Master File (DMF) MCQs With Answer
This quiz collection is designed for M.Pharm students specializing in Documentation & Regulatory Writing. It focuses on Drug Master Files (DMFs), a critical regulatory submission that provides confidential manufacturing, quality, and control information about drug substances, excipients, and packaging components. The questions explore DMF types, structure (CTD relevance), submission practices (LOA, eCTD), regulatory interactions, confidentiality, and global differences such as ASMF/CEP. The objective is to strengthen conceptual understanding and application of DMF requirements in regulatory submissions, manufacturing oversight, and dossier referencing for generics and innovator products. Answers are provided to aid self-assessment and deeper study.
Q1. What is the primary purpose of a Drug Master File (DMF)?
- To provide a marketing authorization for a drug product
- To supply confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drug substances or components
- To replace the need for an active substance specification in the final dossier
- To certify compliance with Good Manufacturing Practices (GMP) by the regulatory authority
Correct Answer: To supply confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drug substances or components
Q2. Which CTD module mainly corresponds to the technical content typically submitted in a DMF?
- Module 1 — Administrative and prescribing information
- Module 2 — Common Technical Document summaries
- Module 3 — Quality (Chemistry, Manufacturing and Controls)
- Module 4 — Nonclinical study reports
Correct Answer: Module 3 — Quality (Chemistry, Manufacturing and Controls)
Q3. Which DMF type (as commonly used by FDA) is primarily intended for drug substance information?
- Type I — Manufacturing site information
- Type II — Drug substance, drug substance intermediate, and material used in their preparation
- Type III — Packaging materials
- Type IV — Excipients, colorants, or materials used in their preparation
Correct Answer: Type II — Drug substance, drug substance intermediate, and material used in their preparation
Q4. What is a Letter of Authorization (LOA) in the context of DMFs?
- An authorization from the regulatory authority to file a DMF
- A letter from the DMF holder permitting a drug applicant to reference the DMF in a regulatory submission and allowing the agency to review the file
- A certificate confirming GMP compliance issued by the DMF holder
- A commercial agreement between the DMF holder and the drug applicant on pricing
Correct Answer: A letter from the DMF holder permitting a drug applicant to reference the DMF in a regulatory submission and allowing the agency to review the file
Q5. Which statement about confidentiality of DMF contents is correct?
- Once submitted, DMF contents are publicly posted and accessible to all applicants
- DMF contents are confidential and reviewed by regulatory authorities; only authorized applicants with an LOA can reference the data
- The DMF holder must publish the full manufacturing process in the public domain
- Confidentiality is waived after the first regulatory review cycle
Correct Answer: DMF contents are confidential and reviewed by regulatory authorities; only authorized applicants with an LOA can reference the data
Q6. Which of the following is NOT typically included in a comprehensive Type II DMF?
- Detailed manufacturing process description and flow diagrams
- Quality control test methods and specifications
- Clinical pharmacology study reports for the finished drug product
- Stability data and packaging information for the drug substance
Correct Answer: Clinical pharmacology study reports for the finished drug product
Q7. How does an Active Substance Master File (ASMF) used in the EU differ conceptually from a US DMF?
- ASMF is public while DMF is always confidential
- ASMF explicitly separates applicant’s part (closed) and manufacturer’s part (open) to facilitate review; both share responsibilities similar to DMF but under EU procedures
- ASMF replaces the need for a Marketing Authorization Application
- There is no difference; the terms are identical and interchangeable in all regulatory contexts
Correct Answer: ASMF explicitly separates applicant’s part (closed) and manufacturer’s part (open) to facilitate review; both share responsibilities similar to DMF but under EU procedures
Q8. Which format is currently preferred by major regulatory agencies for DMF submission?
- Paper-bound binders only
- Electronic Common Technical Document (eCTD) format
- PDF files uploaded without a dossier structure
- Only email attachments of individual files
Correct Answer: Electronic Common Technical Document (eCTD) format
Q9. If a DMF holder wants an applicant to reference a portion of the DMF but not the entire file, what approach is commonly used?
- Provide a general public summary instead of an LOA
- Submit a redacted copy of the entire DMF to the applicant
- Issue an LOA specifying the exact sections and purpose for which the applicant is authorized to reference the DMF
- Transfer full ownership of the DMF to the applicant permanently
Correct Answer: Issue an LOA specifying the exact sections and purpose for which the applicant is authorized to reference the DMF
Q10. Which regulatory action typically occurs if a DMF is not updated in response to regulator deficiency letters or new data?
- The DMF is automatically approved after two years
- The DMF may be placed on inactive or closed status by the regulatory agency, and referenced applications could be affected
- The agency publishes the DMF contents publicly
- The applicant referencing the DMF receives full indemnity
Correct Answer: The DMF may be placed on inactive or closed status by the regulatory agency, and referenced applications could be affected
Q11. For a generic drug applicant, what is the regulatory risk of using an unreferenced DMF (i.e., referencing without LOA)?
- No risk; agency will automatically accept the reference
- Regulatory reviews will be prevented because the agency cannot access confidential DMF information without authorization
- The applicant will be charged double fees
- The DMF holder is compelled to release data publicly
Correct Answer: Regulatory reviews will be prevented because the agency cannot access confidential DMF information without authorization
Q12. Which document often accompanies a DMF submission to provide assurance of GMP compliance for the manufacturing site?
- Certificate of Pharmaceutical Product (CPP)
- GMP certificate or a site master file and manufacturing quality agreements
- Marketing Authorization Letter
- Clinical trial protocol
Correct Answer: GMP certificate or a site master file and manufacturing quality agreements
Q13. Which of the following best describes a “closed” vs “open” part in a regulatory master file context?
- “Closed” parts are encrypted files that cannot be opened; “open” parts are plain text files
- “Closed” (manufacturer’s) part contains confidential manufacturing/process details not shared with the applicant; “open” (applicant’s) part contains information the applicant includes in its dossier
- “Closed” parts are for controlled substances only; “open” parts are for excipients
- There is no such concept in master files; all parts are publicly accessible
Correct Answer: “Closed” (manufacturer’s) part contains confidential manufacturing/process details not shared with the applicant; “open” (applicant’s) part contains information the applicant includes in its dossier
Q14. Which type of DMF would be most appropriate for packaging materials such as blister foil used in the final drug product?
- Type II
- Type III
- Type IV
- Type V
Correct Answer: Type III
Q15. What is an acceptable way for a DMF holder to provide analytical method validation data while protecting proprietary details?
- Refuse to provide any validation data and claim full confidentiality
- Provide method summary and validation results in the DMF’s closed section while giving the applicant sufficient method description or verification protocol as per LOA terms
- Publish the complete method in a scientific journal and cite it
- Send raw instrument files to the applicant without context
Correct Answer: Provide method summary and validation results in the DMF’s closed section while giving the applicant sufficient method description or verification protocol as per LOA terms
Q16. Which is TRUE regarding the FDA’s Type V DMF?
- Type V is used for drug substance only and cannot cover excipients
- Type V is for FDA-accepted reference information that does not fit into Types II–IV and requires prior agreement with FDA
- Type V DMFs are publicly posted on the FDA website automatically
- There is no regulatory distinction; Type V is deprecated
Correct Answer: Type V is for FDA-accepted reference information that does not fit into Types II–IV and requires prior agreement with FDA
Q17. When preparing a DMF to support an ANDA, which of the following must the generic applicant ensure?
- The applicant owns the DMF copyright
- The applicant has a valid LOA or access to necessary information so the regulatory agency can review the referenced DMF
- The applicant only needs to reference the DMF in the bibliographic section without any formal authorization
- The applicant must submit a separate DMF identical to the holder’s file
Correct Answer: The applicant has a valid LOA or access to necessary information so the regulatory agency can review the referenced DMF
Q18. Which of the following best describes the role of stability data in a DMF?
- Stability data are irrelevant for DMFs and only required in the finished product dossier
- Stability data for the drug substance or excipient demonstrate that material retains its key quality attributes over intended storage conditions and are important in DMFs
- Only accelerated stability is acceptable in DMFs; long-term data are prohibited
- Stability testing is replaced by supplier certificates of analysis in all cases
Correct Answer: Stability data for the drug substance or excipient demonstrate that material retains its key quality attributes over intended storage conditions and are important in DMFs
Q19. If a DMF holder changes the manufacturing site for the active substance, what is the appropriate regulatory action?
- No action required; site changes are internal matters
- Submit an update or amendment to the DMF describing the new site, manufacturing process changes if any, and provide supporting GMP information and validation as required by the agency
- Withdraw the DMF permanently and start a new one without notifying applicants
- Only send a verbal notification to the regulatory reviewer
Correct Answer: Submit an update or amendment to the DMF describing the new site, manufacturing process changes if any, and provide supporting GMP information and validation as required by the agency
Q20. Which document or certificate is commonly used in Europe as an alternative to a DMF for demonstrating compliance with monograph standards?
- Certificate of Analysis (CoA)
- European Pharmacopoeia Certificate of Suitability (CEP)
- Investigational New Drug (IND) approval
- Certificate of Pharmaceutical Manufacturing (CPM)
Correct Answer: European Pharmacopoeia Certificate of Suitability (CEP)
